s that come to dominance for each cancer and these have to be circumvented. So far after one year of clinical trial treatment on the combined pill, Dabrafenib and Trametinib, 41% of melanoma patients were progress-free compared with only 9% in the monotherapy Dabrafenib arm. The inhibitor combination also

dient be proven before it could be added to another. Just a few months ago, the FDA approved the first combined inhibitor therapy pill for melanoma: Dabrafenib and trametinib, designed to block certain BRAF enzyme pathway genetic mutations. These mutations occur in approximately 50% of melanoma patients an

ce to a drug can quickly evolve from a tiny mutational pool to predominance and tumor level. The inhibitor cocktail that was approved by the FDA is Dabrafenib and trametinib, designed to block certain BRAF enzyme pathway genetic mutations. These mutations occur in approximately 50% of melanoma patients an